Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy

Area of Science:

• Mycology
• Immunology
• Nanotechnology
• Drug Delivery

Background:

• Invasive fungal infections (IFIs) caused by Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus lead to high mortality rates.
• Immunocompromised individuals are at increased risk for IFIs, a population that is growing.
• Current antifungal drugs have limitations including toxicity and insufficient efficacy, necessitating novel therapeutic strategies.

Purpose of the Study:

• To enhance the effectiveness of antifungal drugs by developing targeted liposomes.
• To improve drug delivery specifically to fungal cells, thereby increasing fungicidal activity and reducing host toxicity.

Main Methods:

• Liposomes loaded with amphotericin B were coated with sDectin-2, a mannan-binding domain of the Dectin-2 receptor.
• The binding efficiency of targeted liposomes to fungal extracellular matrices was compared to untargeted liposomes.
• The efficacy of Dectin-2-coated liposomes in reducing fungal growth and viability was assessed against C. albicans, C. neoformans, and A. fumigatus.

Main Results:

• sDectin-2-coated liposomes exhibited significantly higher binding affinity (orders of magnitude) to fungal mannans compared to control liposomes.
• Dectin-2-coated amphotericin B liposomes demonstrated over a log-fold greater efficiency in reducing fungal growth and viability.
• The effective dose of amphotericin B was dramatically decreased when delivered via targeted liposomes.

Conclusions:

• Targeting antifungal-loaded liposomes to fungal cell wall components using Dectin-2 significantly enhances drug efficacy.
• This targeted drug delivery approach holds promise for improving treatment outcomes for life-threatening invasive fungal infections.
• Further research in animal models is warranted to evaluate the therapeutic potential of these targeted liposomal antifungal drugs.